Dossier assessment
Nirmatrelvir/ritonavir (COVID-19) – Benefit assessment acc. to § 35a Social Code Book V
Report documents
-
Extract of dossier assessment
Nirmatrelvir/ritonavir (COVID-19) – Benefit assessment acc. to § 35a Social Code Book V
-
Dossier assessment
Nirmatrelvir/ritonavir (COVID-19) – Benefit assessment acc. to § 35a Social Code Book V
Dossier assessment
Indication:
Adults with COVID-19 who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19
Result of dossier assessment:
Hint of major added benefit
Press releases
COVID-19: Nirmatrelvir/ritonavir reduces the risk of severe illness in at-risk patients
Due to contraindications and interactions, the drug combination is not suitable for all patients at increased risk.
Project details
- Project no.
- A22-64
- Commission
- Commission awarded on 29.06.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.